IP Library Granted Patent US 10,117,913
Granted Patent B2
US 10,117,913 · App. 15/305,190 · Granted Nov 6, 2018

Antigens of

Inventors: Judd E. Shellito (New Orleans, LA); Alistair John Ramsay (New Orleans, LA); David A. Welsh (New Orleans, LA); Sanbao Ruan (New Orleans, LA); Yang Cai (New Orleans, LA)
Assignees: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY; THE UNIVERSITY OF NEW ORLEANS
A61K39/0002A61K39/00C07K16/40C12N9/48A61K2039/55566
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,117,913
App. No.
15/305,190
Granted
Nov 6, 2018
Kind
B2
Abstract

A surface protein of the murine fungal pathogen Pneumocystis murina can be used to generate an immune response in a recipient animal or human that provides prophylactic protection and an anti-fungal activity in subjects already infected with a Pneumocystis species. Further, the disclosure provides novel polypeptides or peptides derived from the P. murina surface protein Surface Peptidase 1 (SPD-1) that are useful, alone or in combination with the SPD-1 polypeptide, in compositions and methods for the generation of an anti- Pneumocystis immune reaction by a recipient subject. The compositions and methods of the disclosure provide advantageous alternatives to available immunogenic determinants for the treatment or prevention of fungal pneumonia.

Claims (6)

1. An immunogenic composition comprising an isolated Surface Peptidase 1 (SPD-1) polypeptide of Pneumocystis murina and having the sequence according to SEQ ID NO: 1 or an immunogenic fragment thereof, wherein the fragment has an amino acid sequence of at least 90% similarity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 2 and 4, and wherein the composition further comprises a pharmaceutically acceptable carrier and an adjuvant, wherein the adjuvant is MF-59, and is formulated to induce an anti- Pneumocystis immune response when administered to an animal or human recipient.

2. The composition of claim 1 , wherein the immunogenic fragment of the SPD-1 polypeptide has an amino acid sequence SEQ ID NOs: 1, 2 or 4.

3. The composition of claim 1 , wherein the immunogenic fragment of the SPD-1 polypeptide has the amino acid sequence SEQ ID NO: 2 or SEQ ID NO: 4.

4. A method of generating an immune response to a Pneumocystis infection in an animal comprising administering to said animal the immunogenic composition of claim 1 .

5. The method of claim 4 , wherein the Pneumocystis infection is in a human and the infectious agent is P. jirovecii.

6. A kit comprising a container containing a therapeutic amount of an immunogenic composition according to claim 1 and instructions directing the use of the composition in generating an immune response in a recipient animal or human.

Assignments (3)
CONFIRMATORY LICENSE Recorded Nov 30, 2017
From: LSU HEALTH SCIENCES CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044554/0113 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2016
From: CAI, YANG
To: THE UNIVERSITY OF NEW ORLEANS
Reel/Frame 040734/0670 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2016
From: SHELLITO, JUDD E.; WELSH, DAVID A.; RAMSAY, ALISTAIR JOHN; RUAN, SANBAO
To: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
Reel/Frame 040735/0234 →
Continuity (2)
Provisional Application 61988601 · May 5, 2014
Related Publication 20170042988A1 · Feb 16, 2017